Windtree Therapeutics (NASDAQ: WINT) is one of 93 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Windtree Therapeutics to related companies based on the strength of its valuation, risk, earnings, profitability, analyst recommendations, dividends and institutional ownership.

Analyst Ratings

This is a breakdown of current ratings and price targets for Windtree Therapeutics and its rivals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Windtree Therapeutics 0 1 1 0 2.50
Windtree Therapeutics Competitors 163 542 1199 16 2.56

Windtree Therapeutics currently has a consensus target price of $8.00, suggesting a potential upside of 4,002.56%. As a group, “Biotechnology” companies have a potential upside of 54.57%. Given Windtree Therapeutics’ higher possible upside, analysts clearly believe Windtree Therapeutics is more favorable than its rivals.

Insider and Institutional Ownership

36.8% of Windtree Therapeutics shares are owned by institutional investors. Comparatively, 20.4% of shares of all “Biotechnology” companies are owned by institutional investors. 1.3% of Windtree Therapeutics shares are owned by insiders. Comparatively, 20.1% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Windtree Therapeutics and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Windtree Therapeutics $3.23 million -$28.34 million -0.04
Windtree Therapeutics Competitors $223.74 million $57.84 million -0.62

Windtree Therapeutics’ rivals have higher revenue and earnings than Windtree Therapeutics. Windtree Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility & Risk

Windtree Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. Comparatively, Windtree Therapeutics’ rivals have a beta of 1.14, indicating that their average stock price is 14% more volatile than the S&P 500.


This table compares Windtree Therapeutics and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Windtree Therapeutics -588.67% N/A -308.95%
Windtree Therapeutics Competitors -917.30% -187.05% -24.43%


Windtree Therapeutics rivals beat Windtree Therapeutics on 7 of the 12 factors compared.

Windtree Therapeutics Company Profile

Windtree Therapeutics, Inc., formerly Discovery Laboratories, Inc., is a biotechnology company. The Company is focused on developing KL4 surfactant therapies for respiratory diseases and other potential applications. The Company operates through the research and development of products focused on surfactant therapies for respiratory disorders and diseases, and the manufacture and commercial sales of approved products segment. The Company’s technology platform includes a synthetic, peptide-containing surfactant (KL4 surfactant) that is structurally similar to endogenous pulmonary surfactant, and drug delivery technologies being developed to enable non-invasive administration of aerosolized KL4 surfactant. The Company’s core development program, AEROSURF (lucinactant for inhalation), is focused on improving the management of respiratory distress syndrome (RDS) in premature infants, a respiratory condition that can result in long-term respiratory problems, developmental delay and death.

Receive News & Stock Ratings for Windtree Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics Inc and related stocks with our FREE daily email newsletter.